Stock 600993 MAYINGLONG PHARMACEUTICAL GROUP CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Mayinglong Pharmaceutical Group Co., LTD.

Equities

600993

CNE000001HN2

Pharmaceuticals

End-of-day quote Shanghai S.E.
Other stock markets
 06:00:00 2024-06-06 pm EDT 		5-day change 1st Jan Change
28.88 CNY -0.99% Intraday chart for Mayinglong Pharmaceutical Group Co., LTD. +3.85% +19.44%
Apr. 19 Mayinglong Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Apr. 17 Mayinglong Pharmaceutical Receives Registration Approval for New Colorectal Treatment MT

Valuation

Fiscal Period: December 2023 2024 2025 2026
Capitalization 1 10,423 12,449 - -
Enterprise Value (EV) 1 10,423 12,449 12,449 12,449
P/E ratio - - - -
Yield - - - -
Capitalization / Revenue 3.32 x 3.46 x 3.06 x 2.73 x
EV / Revenue 3.32 x 3.46 x 3.06 x 2.73 x
EV / EBITDA - 19.9 x 17.2 x 14.4 x
EV / FCF - 35.5 x 35.2 x 19.8 x
FCF Yield - 2.82% 2.84% 5.05%
Price to Book - 3.02 x 2.73 x 2.44 x
Nbr of stocks (in thousands) 431,054 431,054 - -
Reference price 2 24.18 28.88 28.88 28.88
Announcement Date 4/12/24 - - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2023 2024 2025 2026
Net sales 1 3,137 3,600 4,067 4,559
EBITDA 1 - 626 723 865
EBIT 1 - 657 747 899
Operating Margin - 18.25% 18.37% 19.72%
Earnings before Tax (EBT) - - - -
Net income 443.3 - - -
Net margin 14.13% - - -
EPS - - - -
Free Cash Flow 1 - 350.5 353.8 628.8
FCF margin - 9.74% 8.7% 13.79%
FCF Conversion (EBITDA) - 55.99% 48.94% 72.7%
FCF Conversion (Net income) - - - -
Dividend per Share - - - -
Announcement Date 4/12/24 - - -
1CNY in Million
Estimates

Balance Sheet Analysis

Fiscal Period: December 2023 2024 2025 2026
Net Debt - - - -
Net Cash position - - - -
Leverage (Debt/EBITDA) - - - -
Free Cash Flow 1 - 350 354 629
ROE (net income / shareholders' equity) - 13.4% 13.8% 14.8%
ROA (Net income/ Total Assets) - 10.7% 11.1% 12%
Assets - - - -
Book Value Per Share 2 - 9.560 10.60 11.80
Cash Flow per Share - - - -
Capex 1 - 71 176 80.6
Capex / Sales - 1.97% 4.32% 1.77%
Announcement Date 4/12/24 - - -
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
28.88 CNY
Average target price
35 CNY
Spread / Average Target
+21.19%
Consensus

Chiffre d''affaires - Rate of surprise

Company calendar

Sector Generic Pharmaceuticals

1st Jan change Capi.
MAYINGLONG PHARMACEUTICAL GROUP CO., LTD. Stock Mayinglong Pharmaceutical Group Co., LTD.
+19.44% 1.72B
SUN PHARMACEUTICAL INDUSTRIES LTD. Stock Sun Pharmaceutical Industries Ltd.
+20.14% 43.3B
OTSUKA HOLDINGS CO., LTD. Stock Otsuka Holdings Co., Ltd.
+23.67% 22.22B
SANDOZ GROUP AG Stock Sandoz Group AG
+15.89% 15.43B
CIPLA LIMITED Stock Cipla Limited
+23.10% 14.48B
ZYDUS LIFESCIENCES LIMITED Stock Zydus Lifesciences Limited
+57.58% 12.72B
THE MEDICINES COMPANY Stock The Medicines Company
-0.05% 6.79B
ONO PHARMACEUTICAL CO., LTD. Stock Ono Pharmaceutical Co., Ltd.
-10.69% 6.71B
STADA ARZNEIMITTEL Stock STADA Arzneimittel
-8.87% 5.73B
ASPEN PHARMACARE HOLDINGS LIMITED Stock Aspen Pharmacare Holdings Limited
+14.68% 5.5B
Generic Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 600993 Stock
  4. Financials Mayinglong Pharmaceutical Group Co., LTD.